Interview: Ellson Chen, President & CEO, Vita Genomics, Taiwan
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
Address: 7 Fl., No. 6, Sec. 1, Jung-Shing Road, Wugu Shiang, Taipei, Taiwan
Tel: (+886) 2-8976-9123
Web: http://www.vitagenomics.com/
Vita Genomics, founded in March 2001, has established its headquarter in Taiwan, a marketing office in California, USA, and a wholly owned subsidiary GeneCore in Shanghai, China. Vita Genomics has envisioned itself to be an important player in the healthcare industry by offering advanced and targeted molecular diagnostic products and services, providing more efficient and safer medical solutions, improving the drug development process, and lowering the overall healthcare cost through the pharmacogenomics approaches.Vita Genomics has already built up strong relationships with research institutions and medical organizations throughout Taiwan and China. We are constantly looking for pharmaceutical partners who can benefit from identifying patients for drug responsiveness prior to treatments, partners who would fund expanded pharmacogenomics studies that will enable us to validate the responsiveness of all significant genotypes, and partners who would co-develop DNA-based molecular diagnostic products. Vita Genomics is an active participant in modernizing Taiwan healthcare system. We are establishing the infrastructure needed to add the molecular profile information to the healthcare integrated circuit (IC) card. This is a first step in creating personalized medicine in the future. In addition, Vita Genomics can act as the conduit between the western world and China because we have already established a beachhead in Shanghai.
Vita Genomics follows the high standards of US FDA guidelines in collecting samples in conducting research and clinical studies.Vita Genomics concentrates on the elucidation of the genes and pathways involved in various diseases and on the drug responsiveness of patients in an attempt to improve the healthcare system.
The President & CEO of Vita Genomics talks about the advantages that genomic testing offer both to sick and healthy patients, as well as the opportunities to catalogue the science…
Nutrarex Biotech is a Taiwanese private label contract manufacturer of functional supplements, exclusively representing a number of cutting-edge raw materials from Europe, the US, and Japan. Stanley Huang is the…
In an effort to enhance trade and cooperation with other countries in the region and reduce dependency on mainland China, in 2016 Taiwan’s government introduced the New Southbound Policy (NSP).…
Within Taiwan’s evolving medical device sector, many innovative startups are exploring breakthrough ideas which are sparking global interest and attention – iXensor being a chief example. The company’s patented technology…
Mark Yang, CEO of GaleMed, elaborates on the medical device manufacturer’s transition from a privately-owned company to being acquired by private equity firm Nexus Point Capital. Yang goes on to…
United Biomedical, Inc. (UBI) is dedicated to the discovery, development, and commercialization of immunotherapies & vaccines for chronic and infectious diseases and is passionate about delivering science-driven innovation with platform…
James Chiu, GM of Fresenius Kabi Taiwan, discusses the affiliate’s portfolio offering of parenteral and enteral nutrition in Taiwan as well as its move towards biosimilars. In addition, Chiu highlights…
Shuhei Sekiguchi, recently-appointed managing director of Janssen Taiwan, discusses how his vast experience in marketing and sales will help him in this new role, Janssen´s market outlook for Taiwan, its…
The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each…
G-SYN Biomedical Technology is a company dedicated to resolving problems occurring from cell hypoxia. Dieter Chang, the company’s founder introduces the firm, why they decided to focus on hypoxia, their…
Philip Chen, chairman of the Taipei Exchange, discusses the capital market condition, elaborates on the significance of biotech, and shares the competitive advantages of innovation companies listing on TPEx. Chen…
Danny Liao, CEO of Taiwanese diagnostics firm Skyla discusses the reason behind splitting from parent company Lite-On, the thinking behind a move from information technology (IT) into medical diagnostics and…
The Southern Taiwan Science Park (STSP)’s Chen-Kang Su discusses how STSP has played a key role in bringing innovation to Taiwan, how collaborations between academic institutions and industry are helping…
See our Cookie Privacy Policy Here
